Alkem Reduces Prices of Denuril, Brand of Denosumab by 30% for the Treatment of Osteoporosis in Postmenopausal Women

One of India's leading drug makers, Alkem Labs, has recently announced the reduction in the price of Denosumab injection sold under the brand name Denuril.

Denuril, which contains Denosumab, is approved by DCGI for the treatment of osteoporosis in postmenopausal women.

It is available as a single-dose prefilled syringe containing 60 mg per 1 ml solution for subcutaneous injection.

In an endeavor to increase adherence and affordability of osteoporosis treatment, Alkem has slashed the price of its No. 1* prescribed Denosumab brand in India by more than 30%. Denuril injection, which was earlier costing INR 12499/-, will now be available at INR 8625/-.

Denosumab is a novel bone anti-resorptive agent used for the treatment of osteoporosis. It is a human IgG2 monoclonal antibody acting as Receptor Activator of Nuclear Factor kappa-Β Ligand (RANKL) inhibitor. It blocks osteoclast maturation and bone resorption.

The multicentric FREEDOM trial suggested that Denosumab treatment for up to 10 years was associated with low fracture incidence and low rates of adverse events among postmenopausal women with osteoporosis.

Alkem remains dedicated to advancing healthcare solutions to a larger section of the population and positively impact their lives. As per day cost of Denosumab comes down to around Rs 48.

*IQVIA RXN DATA OCT ’23 

Disclaimer: This post has been published under MD Brand Connect Initiative and is sponsored by Alkem Laboratories Limited.